114676-47-0

Basic information

• Product Name: CIS-4-HYDROXY-D-PROLINE METHYL ESTER
• Synonyms: D-Proline, 4-hydroxy-, methyl ester, (4R)- (9CI);(2R,4R)-methyl 4-hydroxypyrrolidine-2-carboxylate;(2R,4R)-4-Hydroxypyrrolidine-2-carboxylic acid methyl ester;(2R,4R)-rel-methyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride;CIS-4-HYDROXY-D-PROLINE METHYL ESTER;Cis-4-OH-D-Pro-Ome
• CAS NO: 114676-47-0
• Molecular Formula: C₆H₁₁NO₃
• Molecular Weight: 145.16
• Product Categories: CARBOXYLICESTER
• Mol File: 114676-47-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 247.2 °C at 760 mmHg
• Flash Point: 103.3 °C
• Appearance: /
• Density: 1.216 g/cm³
• Vapor Pressure: 0.00426mmHg at 25°C
• Refractive Index: 1.487
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CIS-4-HYDROXY-D-PROLINE METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-4-HYDROXY-D-PROLINE METHYL ESTER(114676-47-0)
• EPA Substance Registry System: CIS-4-HYDROXY-D-PROLINE METHYL ESTER(114676-47-0)

Safety Data

• Hazardous Substances Data: 114676-47-0(Hazardous Substances Data)

Usage

General Description

CIS-4-HYDROXY-D-PROLINE METHYL ESTER is a chemical compound, often used in the fields of biochemistry and pharmaceuticals. It its own, this compound is a derivative of proline, which is one of the twenty primary amino acids used by living organisms to synthesize proteins. The methyl ester variation of this compound is usually created by a reaction of the hydroxyproline with methanol under acidic conditions. It serves as a key component in several biochemical reactions, mostly related to the production of collagen, a crucial protein for human skin, bones, and connective tissues. Its other roles include possible use in drug synthesis and other medicinal applications.

InChI:InChI=1/C6H11NO3/c1-10-6(9)5-2-4(8)3-7-5/h4-5,7-8H,2-3H2,1H3/t4-,5-/m1/s1

Upstream product

• 67-56-1 methanol 
• 1064036-63-0 (2R,4R)-4-Hydroxy-pyrrolidine-2-carbonyl chloride 
• 176966-56-6 (2R,4R,1'S)-1-(1'-phenylethyl)-4-hydroxy-proline methyl ester 
• 2584-71-6 cis-hydroxy-D-proline 
• 51-35-4 4R-4-hydroxyproline 
• 77449-94-6 (2R,4R)-4-hydroxypyrrolidine-2-carboxylic acid hydrochloride 
• 75-36-5 acetyl chloride 

Downstream Products

• 114676-69-6 (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 141850-54-6 (2R,4R)-tert-butyl 4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 1562988-38-8 (S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester 
• 1271809-99-4 methyl (2R,4R)-1-benzyl-4-[tert-butyl(dimethyl)silyl]oxy-pyrrolidine-2-carboxylate 
• 635299-81-9 [(2R,4R)-1-benzyl-4-[tert-butyl(dimethyl)silyl]oxy-pyrrolidin-2-yl]methanol 
• 708253-90-1 [(3R,5S)-5-azido-1-benzyl-3-piperidyl]oxy-tert-butyl-dimethylsilane 
• 708253-91-2 tert-butyl N-[(3S,5R)-1-benzyl-5-[tert-butyl(dimethyl)silyl]oxy-3-piperidyl]carbamate 
• 1187055-35-1 benzyl (3S,5R)-3-(tert-butoxycarbonylamino)-5-[tert-butyl(dimethyl)silyl]oxy-piperidine-1-carboxylate 
• 1187055-40-8 benzyl (3S)-3-(tert-butoxycarbonylamino)-5-oxo-piperidine-1-carboxylate 
• 1187055-41-9 benzyl (5S)-5-(tert-butoxycarbonylamino)-3,3-difluoropiperidine-1-carboxylate 
• 114676-53-8 (2R,4R)-methyl 1-benzyl-4-hydroxypyrrolidine-2-carboxylate 
• 155075-23-3 (2R,4R)-1-benzyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 1611487-81-0 N-((3S,5S)-5-fluoropiperidin-3-yl)benzamide 
• 1611481-37-8 N-((3S,5R)-5-(hydroxymethyl)-1-tritylpyrrolidin-3-yl)benzamide 

Relevant articles and documents

Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II

A series of D-proline peptidomimetics were evaluated as dual inhibitors of both human carbonic anhydrases (hCAs) and human gelatinases (MMP2 and MMP9), as these enzymes are both involved in the carcinogenesis and tumor invasion processes. The synthesis and enzyme inhibition kinetics of D-proline derivatives containing a biphenyl sulfonamido moiety revealed an interesting inhibition profile of compound XIV towards MMP9 and CAII. The SAR analysis and docking studies revealed a stringent requirement of a trans geometry for the two arylsulfonyl moieties, which are both necessary for inhibition of MMP9 and CAII. As MMP9 and CAII enzymes are both overexpressed in gastrointestinal stromal tumor cells, this molecule may represent an interesting chemical probe for a multitargeting approach on gastric and colorectal cancer.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.